Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

3 Months Ended

Oct. 31, 2016

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	18,558			—			—			—		$	18,558
Product revenues		—		$	7,426			—			—			7,426
Royalty and license fee income		—			300			—			—			300
		18,558			7,726			—			—			26,284
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		10,896			—			—			—			10,896
Cost of product revenues		—			3,309			—			—			3,309
Research and development		—			627		$	195			—			822
Selling, general and administrative		5,952			2,946			—		$	2,576			11,474
Provision for uncollectible accounts receivable		666			3			—			—			669
Legal fee expense		52			12			—			308			372
Legal settlements, net		—			—			—			—			—
Total operating costs, expenses and legal settlements, net		17,566			6,897			195			2,884			27,542

Operating income (loss)		992			829			(195	)		(2,884	)		(1,258	)

Other income (expense):
Interest		(29	)		10			—			65			46
Other		102			—			—			17			119
Foreign exchange loss		—			(361	)		—			—			(361	)
Income (loss) before income taxes	$	1,065		$	478		$	(195	)	$	(2,802	)	$	(1,454	)

Depreciation and amortization included above	$	401		$	508		$	—		$	18		$	927

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			—			—			—			—
Selling, general and administrative		17		$	11			—		$	121			149
Total	$	19		$	11		$	—		$	121		$	151

Capital expenditures	$	412		$	102		$	—		$	—		$	514

Three months ended October 31, 2015	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	17,090			—			—			—		$	17,090
Product revenues		—		$	7,687			—			—			7,687
Royalty and license fee income		—			400			—			—			400
		17,090			8,087			—			—			25,177
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services		10,332			—			—			—			10,332
Cost of product revenues		—			3,611			—			—			3,611
Research and development		—			667		$	200			—			867
Selling, general and administrative		5,286			3,059			—		$	1,880			10,225
Provision for uncollectible accounts receivable		708			(4	)		—			—			704
Legal fee expense		9			(22	)		—			1,614			1,601
Legal settlement, net		—			(6,800	)		—			—			(6,800	)
Total operating costs, expenses and legal settlements, net		16,335			511			200			3,494			20,540

Operating income (loss)		755			7,576			(200	)		(3,494	)		4,637

Other income (expense):
Interest		(19	)		14			—			(35	)		(40	)
Other		4			39			—			11			54
Foreign exchange loss		—			(130	)		—			—			(130	)
Income (loss) before income taxes	$	740		$	7,499		$	(200	)	$	(3,518	)	$	4,521

Depreciation and amortization included above	$	397		$	530		$	—		$	23		$	950

Share-based compensation included in above:
Cost of clinical laboratory services	$	1			—			—			—		$	1
Research and development		—		$	—			—			—			—
Selling, general and administrative		10			5			—		$	95			110
Total	$	11		$	5		$	—		$	95		$	111

Capital expenditures	$	437		$	68		$	—		$	—		$	505